New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Stereotactic Ablative Radiotherapy for Central and Ultra-Central Lung Tumors.
Stereotactic Ablative Radiotherapy for Central and Ultra-Central Lung Tumors. Therapeutic radiology and oncology Chaudhuri, A. A., Chen, K. n., Diehn, M. n., Loo, B. W. 2019; 3Abstract
Stereotactic ablative radiotherapy (SABR) has emerged as a standard-of-care treatment for patients with early stage non-small cell lung cancer (NSCLC) who are poor surgical candidates. Current evidence supports the consensus that lung SABR with BED =100 Gy leads to high local tumor control, and that the treatment is generally well-tolerated when applied to peripheral lung tumors. However, several studies present conflicting evidence for the treatment of central and ultra-central lung tumors, with some showing superb outcomes and others showing concerning rates of morbidity and mortality. Therefore, treatment of central and especially ultra-central lung tumors with SABR remains controversial. In this review, we aim to present the existing evidence for SABR treatment of central and ultra-central lung tumors and delineate the factors that could lead to significant toxicity.
View details for DOI 10.21037/tro.2019.05.01
View details for PubMedID 33880444
View details for PubMedCentralID PMC8054989